SCHEMBL14745679

SCHEMBL14745679

COC(=O)c1cc2c(n(Cc3ccc(OC)cc3OC)c1=O)-c1cc3cc(CO)n(C)c3cc1CCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRG2 P18507 5/20 0.37
GABRB3 P28472 5/20 0.37
GABRA3 P34903 5/20 0.37
GABRA2 P47869 4/20 0.37
GABRA1 P14867 3/20 0.37
GABRA5 P31644 2/20 0.37
TSHR P16473 2/20 0.35
NPC1 O15118 1/20 0.35
PKM P14618 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TAS1R3 Q7RTX0 1/20 0.35
TAS1R1 Q7RTX1 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
MTNR1A P48039 1/20 0.34
MTNR1B P49286 1/20 0.34
LMNA P02545 3/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
F2 P00734 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745689 0.93 SMN1; SMN2 (0.37) TSHRNPC1PKMRAB9ASMN1; SMN2
SCHEMBL14746068 0.88 AADAT (0.33) GABRG2GABRB3GABRA3GABRA2GABRA1
SCHEMBL14746181 0.86 EGLN1 (0.37) TSHRNPC1PKMRAB9ASMN1; SMN2
SCHEMBL14745710 0.85 EGLN1 (0.37) TSHRNPC1PKMRAB9ASMN1; SMN2
SCHEMBL14746097 0.83 EGLN1 (0.38) TSHRNPC1PKMRAB9AL3MBTL1
SCHEMBL16429014 0.82 EDNRB (0.39) TSHRSMN1; SMN2ALDH1A1MAPTHSD17B10
SCHEMBL14746069 0.81 TSHR (0.38) TSHRNPC1PKMRAB9ASMN1; SMN2
SCHEMBL14746160 0.81 EDNRB (0.39) TSHRSMN1; SMN2ALDH1A1MAPTHSD17B10
SCHEMBL14745624 0.80 GABRG2 (0.40) GABRG2GABRB3GABRA3GABRA2GABRA1
SCHEMBL14745792 0.79 GABRG2 (0.44) GABRG2GABRB3GABRA3GABRA2GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2750678-B1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS INC (US) 2017-03-22 EP disclosed
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. 2015-02-05 US disclosed
EP-2750678-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033228-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038438-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP GABRG2 3111/4885GABRB3 2579/4885GABRA3 3572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.